The content on this site is intended for healthcare professionals only
Prof Michail Ignatiadis talks to ecancer about neoadjuvant therapy and pathological complete response (PCR) at IMPAKT 2012 in Brussels, May 2012.
The study conducted looks at whether or not neoadjuvant therapy should be used in order to reach pathological complete response. Results have shown that this can occur after commonly used therapies.
Data shows that patients with HER2 amplified and triple negative tumours have excellent response when receiving chemotherapy before surgery. After treatment, biopsies can be used to determine tumour type and its sensitivity to chemotherapy for future record. The most important finding in the study was that the immune response module had a signficantly higher probability of complete pathological response.
Filming Supported by Amgen
Clinical behaviour of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing
Multiple myeloma in a resource constrained setting
SABCS 2023: Latest breast cancer diagnostics guidelines
Genomic testing: Awareness and effective communication between healthcare professionals and patients
Short-course radiation as effective as standard treatment for breast cancer patients choosing reconstruction after mastectomy
War in Ukraine: The Global Medical Knowledge Alliance's response to improving cancer care
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Precision oncology: Present and future in breast cancer
The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival
